Severe and delayed-onset acneiform eruptions as an adverse reaction to regorafenib

Regorafenib is an oral multikinase inhibitor targeting several tyrosine kinase receptors including BRAF and epidermal growth factor receptor (EGFR) and is approved as a third-line treatment for metastatic gastrointestinal stromal tumor (GIST). While acneiform eruptions have been observed in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Otsuka, Haruhiko, Fukumoto, Takeshi, Kiyota, Naomi, Takemori, Chihiro, Jimbo, Haruki, Nishigori, Chikako
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications, Pavia, Italy 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9251528/
https://www.ncbi.nlm.nih.gov/pubmed/35795830
http://dx.doi.org/10.4081/dr.2022.9303

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9251528/
https://www.ncbi.nlm.nih.gov/pubmed/35795830
http://dx.doi.org/10.4081/dr.2022.9303

Ejemplares similares